Status:
COMPLETED
Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature
Lead Sponsor:
Intergroupe Francophone de Cancerologie Thoracique
Collaborating Sponsors:
AstraZeneca
Conditions:
Pneumonic-type Adenocarcinoma (P-ADC)
Lung Adenocarcinoma With Bronchiolo-alveolar Feature
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Pneumonic adenocarcinoma (P-ADC) is defined as a primary lung ADC with a radiological pneumonic presentation, usually referred to histologically as ADC with a mixed-invasive and BAC predominant subtyp...
Detailed Description
We therefore conducted a French multicentric phase II trial (IFCT 0401) to evaluate activity and tolerance of gefitinib (250 mg/day) administered as first line treatment in patients with non-resectabl...
Eligibility Criteria
Inclusion
- Pathologically / cytologically proven ADC-P
- Non-resectable disease
- 3-month expected survival
- No prior radiotherapy or chemotherapy
- Age \>= 18 years old
- Performance status \< 4 (WHO)
- Adequate blood biological parameters
Exclusion
- Abnormal initial fibroscopy
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00198380
Start Date
April 1 2005
End Date
December 1 2009
Last Update
March 8 2024
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Besancon - Pneumologie
Besançon, France, 25000
2
APHP - CHU Avicenne - Oncologie Medicale
Bobigny, France, 93000
3
Centre F. Baclesse
Caen, France, 14000
4
CHU - Pneumologie
Caen, France, 14000